By Court Wing Taking a deep look at the trial’s Supplementary Appendix, the response from the psychedelic science community, and the choice to measure the results using the QIDS depression rating scale. On April 15, 2021 the New England Journal of Medicine published a study comparing the efficacy of psilocybin-assisted therapy to a popular SSRI …

The post Op-Ed: Re-evaluating the Results of the Recent Trial of Psilocybin vs Escitalopram for Depression appeared first on Psychedelics Today.

Previous articleBexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation
Next articleCOMPASS Pathways announces pricing of public offering